# EDGAR Filing Document

**Accession Number:** 0001661059
**File Stem:** 0001213900-25-078679
**Filing Date:** 2025-8
**Character Count:** 29448
**Document Hash:** 70ef9493372853e13c0075c7443e7812
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-078679.hdr.sgml**: 20250819

**ACCESSION NUMBER**: 0001213900-25-078679

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20250819

**DATE AS OF CHANGE**: 20250819

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NextCure, Inc.
- **CENTRAL INDEX KEY:** 0001661059
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475231247
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91004
- **FILM NUMBER:** 251233693

**BUSINESS ADDRESS:**
- **STREET 1:** 9000 VIRGINIA MANOR ROAD, SUITE 200
- **CITY:** BELTSVILLE
- **STATE:** MD
- **ZIP:** 20705
- **BUSINESS PHONE:** 240-399-4900

**MAIL ADDRESS:**
- **STREET 1:** 9000 VIRGINIA MANOR ROAD, SUITE 200
- **CITY:** BELTSVILLE
- **STATE:** MD
- **ZIP:** 20705
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Simcere Zaiming, Inc.
- **CENTRAL INDEX KEY:** 0002080252

**ORGANIZATION NAME:**
- **EIN:** 922412706
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 20 ACORN PARK DR, CAMBRIDGE, MA 02140
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02140
- **BUSINESS PHONE:** 15049574163

**MAIL ADDRESS:**
- **STREET 1:** 20 ACORN PARK DR, CAMBRIDGE, MA 02140
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02140

## Ex-24

**Exhibit 24**

**POWER OF ATTORNEY**

Know all by these presents, that the undersigned hereby makes, constitutes and appoints Mr. Renhong Tang, a director of the undersigned, with full power of substitution and re-substitution, as the undersigned's true and lawful attorney-in-fact (referred to herein as the "Attorney-in-Fact"), with full power to act for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to:

&nbsp;&nbsp;&nbsp;&nbsp;1. execute for and on behalf of the undersigned, in the undersigned's
capacity as the Legal Presentative and Chairman of the Board of Directors of Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., a limited
liability company incorporated in the P. R. China (the "Company"), any and all forms, schedules, statements and other documents
(including any amendments thereto) ("Filings") that the Company may be required to file with the U.S. Securities and Exchange
Commission ("SEC") under (i) Section 13 or Section 16 of the U.S. Securities Exchange Act of 1934, as amended, and any rule
or regulation thereunder, including without limitation filings on Form 3, Form 4, Form 5, Schedule 13D and Schedule 13G; and (ii) the
U.S. Securities Act of 1933, as amended, and Rule 144 thereunder, including without limitations filings on Form 144.

&nbsp;&nbsp;&nbsp;&nbsp;2. do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and execute any such Filings identified in sub-paragraph (1) above, complete
and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority;
and

&nbsp;&nbsp;&nbsp;&nbsp;3. take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such Attorney-in-Fact, may be of benefit to, in the best interest of, or legally required
by, the Company, it being understood that the documents executed by such Attorney-in-Fact on behalf of the undersigned pursuant to this
Power of Attorney shall be in such form and shall contain such terms and conditions as such Attorney-in-Fact may approve in such Attorney-in-Fact's
discretion.

The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite, necessary or advisable to be done in connection with the foregoing, as fully, to all intents and purposes, as the undersigned might or could do in person, hereby ratifying and confirming all that the Attorney-in-Fact, or his substitute or substitutes, shall lawfully do or cause to be done by authority of this Power of Attorney. The undersigned acknowledges that the Attorneys-in-Fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with the U.S. Securities Exchange Act of 1934, as amended, or any rules thereunder, or the U.S. Securities Act of 1933, as amended, or any rules thereunder.

This Power of Attorney shall remain in full force and effect until the Company is no longer required to make any such Filings, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of August 8, 2025.

[Signature Page to Follow]

---

| | |
|:---|:---|
| **Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.** | **Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.** |
| By: | /s/ Wu Yongmin |
| Name: | Wu Yongmin |
| Title: | Legal Representative and<br> Chairman of the Board of Directors |

---

## Exhibit 99.1

**Exhibit 99.1**

**JOINT FILING AGREEMENT**

This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.001 per share, of NextCure, Inc. is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below that is named as a reporting person in such filing in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated: August 19, 2025

---

| | |
|:---|:---|
| **Simcere Zaiming, Inc.** | **Simcere Zaiming, Inc.** |
| By: | /s/ Renhong Tang |
| Name: | Renhong Tang |
| Title: | Chief Executive Officer |

---

---

| | |
|:---|:---|
| **Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.** | **Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.** |
| By: | /s/ Renhong Tang |
| Name: | Renhong Tang |
| Title: | Director and Attorney-in-Fact |

---

---

| | |
|:---|:---|
| **Hainan Simcere Zaiming Pharmaceutical Co., Ltd.** | **Hainan Simcere Zaiming Pharmaceutical Co., Ltd.** |
| By: | /s/ Renhong Tang |
| Name: | Renhong Tang |
| Title: | Chief Executive Officer and<br> Chairman of the Board of Directors |
| **Simcere Pharmaceutical Group Limited** | **Simcere Pharmaceutical Group Limited** |
| By: | /s/ Jinsheng Ren |
| Name: | Jinsheng Ren |
| Title: | Chief Executive Officer and<br> Chairman of the Board of Directors |

---

---

| | |
|:---|:---|
| **Jinsheng Ren** | **Jinsheng Ren** |
| By: | /s/ Jinsheng Ren |
| Name: | Jinsheng Ren |

---

---

| | |
|:---|:---|
| **Renhong Tang** | **Renhong Tang** |
| By: | /s/ Renhong Tang |
| Name: | Renhong Tang |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** NEXTCURE, INC.

**Title of Class of Securities:** Common Stock, par value $0.001 per share

**CUSIP Number:** 65343E207

**Date of Event Which Requires Filing of this Statement:** 06/20/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Simcere Zaiming, Inc. | Names of Reporting Persons<br>Simcere Zaiming, Inc. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>12.7% | Percent of Class Represented by Amount in Row (9)<br>12.7% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc.

Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).

---

| 1. | Names of Reporting Persons<br>Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. | Names of Reporting Persons<br>Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>12.7% | Percent of Class Represented by Amount in Row (9)<br>12.7% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by  Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.  Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. may deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc.

Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).

---

| 1. | Names of Reporting Persons<br>Hainan Simcere Zaiming Pharmaceutical Co., Ltd. | Names of Reporting Persons<br>Hainan Simcere Zaiming Pharmaceutical Co., Ltd. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>12.7% | Percent of Class Represented by Amount in Row (9)<br>12.7% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by  Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Hainan Simcere Zaiming Pharmaceutical Co., Ltd. may deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc.

Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).

---

| 1. | Names of Reporting Persons<br>Simcere Pharmaceutical Group Limited | Names of Reporting Persons<br>Simcere Pharmaceutical Group Limited |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>12.7% | Percent of Class Represented by Amount in Row (9)<br>12.7% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by  Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Simcere Pharmaceutical Group Limited is the controlling shareholder of Hainan Simcere Zaiming Pharmaceutical Co., Ltd. through investment in several intermediate companies. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Simcere Pharmaceutical Group Limited may be deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc.

Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).

---

| 1. | Names of Reporting Persons<br>Ren Jinsheng | Names of Reporting Persons<br>Ren Jinsheng |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>338636.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>12.7% | Percent of Class Represented by Amount in Row (9)<br>12.7% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** Note to Rows (6), (8) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by  Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Hainan Simcere Zaiming Pharmaceutical Co., Ltd.  Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Pharmaceutical Group Limited and a director of Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Jinsheng Ren may thereby be deemed to beneficially own the 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., sharing the voting power and investment power over such shares with Mr. Renhong Tang.

Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).

---

| 1. | Names of Reporting Persons<br>Tang Renhong | Names of Reporting Persons<br>Tang Renhong |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F4 | Citizenship or Place of Organization<br>F4 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>338636.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>338636.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>338636.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>12.7% | Percent of Class Represented by Amount in Row (9)<br>12.7% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** Note to Rows (6), (8) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by  Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which is 100% owned by Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Renhong Tang is a director of Simcere Pharmaceutical Group Limited, the chief executive officer and chairman of the board of directors of Hainan Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. and the chief executive officer and sole director of Simcere Zaiming, Inc. Accordingly, Mr. Renhong Tang may thereby be deemed to beneficially own the 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., sharing the voting power and investment power over such shares with Mr. Jinsheng Ren.

Note to Row (11): Based on an aggregate of 2,676,152 shares of the Issuer's common stock issued and outstanding as of July 17, 2025 as reported by the Issuer in its Form S-3 filed with the U.S. Securities and Exchange Commission on July 18, 2025 (File No. 333-288763).

---

**Item 1(a). Name of Issuer:**
NEXTCURE, INC.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705

**Item 2(a). Name of Person Filing:**
(i) Simcere Zaiming, Inc., a Delaware corporation ("Simcere Zaiming"), with its principal business address at 20 Acorn Park Dr., Cambridge, MA 02140;

(ii) Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., a limited liability company incorporated in P. R. China ("Jiangsu Zaiming"), is the sole shareholder of Simcere Zaiming, and its principal business address is at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China;

(iii) Hainan Simcere Zaiming Pharmaceutical Co., Ltd., a limited liability company incorporated in P. R. China ("Hainan Zaiming"), is the sole shareholder of Jiangsu Zaiming, and its principal business address is at No 20, Yaoguyiheng Road, Xiuying District, Haikou, Hainan, P. R. China.

(iv) Simcere Pharmaceutical Group Limited, a company incorporated in Hong Kong ("Simcere Group") and the controlling shareholder of Hainan Zaiming through several intermediate companies, and its principal business address is at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China.

(v) Mr. Jinsheng Ren, citizen of People's Republic of China, the chief executive officer and chairman of the board of directors of Simcere Group and a director of Hainan Zaiming, with his business address at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China; and

(vi) Mr. Renhong Tang, citizen of People's Republic of China, a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming, with his business address at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China.

The persons and entities listed in items (i) to (vi) are collectively referred to herein as "Reporting Persons."

The Reporting Persons have entered into a joint filing agreement, a copy of which is attached hereto as Exhibit 99.1.

**Item 2(b). Address of Principal Business Office:**
See Item 2(a) above.

**Item 2(c). Citizenship:**
See Item 2(a) above.

**Item 2(d). Title of Class of Securities:**
Common Stock, par value $0.001 per share

**Item 2(e). CUSIP Number:**
65343E207

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

See Row 9 of the cover page for each Reporting Person.
Each of Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this Schedule 13G shall not be deemed to be an admission that the Reporting Persons hereunder are the beneficial owners of any of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

**(b) Percent of class:**

See Row 11 of the cover page for each Reporting Person.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

See Row 5 of the cover page for each Reporting Person.

**(ii) Shared power to vote or to direct the vote:**

See Row 6 of the cover page for each Reporting Person.

**(iii) Sole power to dispose or to direct the disposition of:**

See Row 7 of the cover page for each Reporting Person.

**(iv) Shared power to dispose or to direct the disposition of:**

See Row 8 of the cover page for each Reporting Person.

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Simcere Zaiming, Inc.**

**Date:** 08/19/2025

**By:** /s/ Renhong Tang

**Name & Title:** Renhong Tang/Chief Executive Officer

**Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.**

**Date:** 08/19/2025

**By:** /s/ Renhong Tang

**Name & Title:** Renhong Tang/Director and Attorney-in-Fact

**Hainan Simcere Zaiming Pharmaceutical Co., Ltd.**

**Date:** 08/19/2025

**By:** /s/ Renhong Tang

**Name & Title:** Renhong Tang/Chief Executive Officer and Chairman of the Board of Directors

**Simcere Pharmaceutical Group Limited**

**Date:** 08/19/2025

**By:** /s/ Jinsheng Ren

**Name & Title:** Jinsheng Ren / Chief Executive Officer and Chairman of the Board of Directors

**Ren Jinsheng**

**Date:** 08/19/2025

**By:** /s/ Jinsheng Ren

**Name & Title:** Jinsheng Ren

**Tang Renhong**

**Date:** 08/19/2025

**By:** /s/ Renhong Tang

**Name & Title:** Renhong Tang